Gollob
David S. Gollob, Simsbury, CT US
Patent application number | Description | Published |
---|---|---|
20090304943 | Method for Forming Ceramic Containing Composite Structure - A method for forming a ceramic containing composite structure is proposed comprising the steps of (a) feeding a ceramic component that sublimes and a metallic or semi-conductor material that does not sublime into a thermal spray apparatus, (b) spraying the ceramic component and the metallic or semi-conductor material onto a substrate, whereby the ceramic component and the metallic or semi-conductor material deposit on the surface of the substrate, and (c) keeping the metallic or semi-conductor material on the substrate surface plastic during spraying at least in the region where the metallic or semi-conductor material actually strikes the surface. | 12-10-2009 |
Jared Gollob, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100168206 | GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 07-01-2010 |
20120282341 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer. | 11-08-2012 |
20130012570 | GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 01-10-2013 |
20140336243 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer. | 11-13-2014 |
Jared Gollob, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20130345286 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a liquid particle formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as endometrial cancer. | 12-26-2013 |
Lawrence Gollob, Stone Mountain, GA US
Patent application number | Description | Published |
---|---|---|
20140275352 | METHODS FOR REDUCING THE SOLUBILITY OF PHENOLIC RESINS USING LATENT ACIDS - Resin compositions having a reduced solubility and methods for making and using same are provided. In at least one specific embodiment, the resin composition can include a phenolic resin, a latent acid, a catalyst, and a liquid medium. The catalyst can be a base compound and can be present in an amount of about 2 wt % to about 7 wt %, based on the combined weight of the phenolic resin, the latent acid, the catalyst, and the liquid medium. | 09-18-2014 |
Michael H. Gollob, Ottawa CA
Patent application number | Description | Published |
---|---|---|
20090054248 | CONNEXIN 40 TISSUE SPECIFIC GENE MUTATIONS - A method of detecting cardiac arrhythmia in a patient is described. This method involves determining whether there is a mutation in the nucleotide sequence, the amino acid sequence, or both, of connexin40 obtained from a patient. The mutation may be localized within the transmembrane domain of connexin40. Furthermore, there is described a method of identifying a compound for the treatment of cardiac arrhythmia. This method involves providing a cell culture that is characterized by having impaired intracellular trafficking, impaired electrical coupling, reduced gap junction plaque formation, reduced intracellular coupling, or a combination thereof, when compared to a wild-type cell. A compound is added to the cell culture, and restoration of intracellular trafficking, electrical coupling, gap junction plaque formation, intracellular coupling, or a combination thereof, is monitored. | 02-26-2009 |
Peter Gollob, Graz AT
Patent application number | Description | Published |
---|---|---|
20110267005 | Active Charge Balancing Circuit - A charge balancing circuit and an energy storage arrangement with a charge balancing circuit are disclosed. | 11-03-2011 |
20130114309 | Battery Module - A battery module and an arrangement including a number of battery modules connected in series are disclosed. An energy store has a positive and a negative connection. A boost converter has a first and a second converter output. The energy store is connected at the positive connection of the energy store to a first connection and at the negative connection of the energy store to a second connection. The first converter output is connected to a first compensation connection and the second converter output is connected to a second compensation connection. The converter is designed to draw energy from the energy store and to provide the energy to the converter outputs of the converter in the form of current. | 05-09-2013 |